A B S T R A C T The hepatic and renal metabolism of somatostatin-like immunoreactivity (SLI) was assessed simultaneously in an in vivo dog model. The hepatic extraction of this peptide was 29.4+±2.3% and was similar for endogenous and infused exogenous SLI. The renal extraction was 62.3±+5%. The renal clearance of SLI was significantly greater than that of inulin indicating that the peptide is handled by peritubular uptake from postglomerular blood in addition to glomerular filtration. In both organs SLI extraction was not saturable even at arterial concentrations in excess of 100 times physiological range. The overall metabolic clearance rate of SLI was 19.7±1.6 ml/kg per minute of which 32.7±4.6% was contributed by hepatic and 37±4.9% by renal uptake mechanisms. The plasma half disappearance time of exogenously infused SLI was 1.9±0.3 min.
INTRODUCTION
Since its discovery in 1973 (1) somatostatin has been the object of intense scientific interest and study. As a result of these investigations a great deal of information is available regarding the distribution of this peptide in various parts of the nervous system (1-4), gut, and pancreas (5), as well as its effect on the secretion of various hormones (1, 6, 7) . Exogenous somatostatin is rapidly metabolized in man, the metabolic clearance rate and plasma half life of infused somatostatinlike immunoreactivity (SLI)1 being 28.7 ml/kg per min and 1.9 min, respectively (8) . The sites of SLI metabolism, however, have not been studied in detail, although there is some evidence that both liver and kidney may be important in this regard. Shapiro et al. (9) measured a significant renal arteriovenous difference in SLI in the rat and suggested that the kidney is an important site of its degradation. This conclusion was further supported by the observation that the metabolic clearance rate of SLI was significantly prolonged in uremia (8) . A number of workers (10) (11) (12) have observed portal peripheral SLI gradients, a finding that suggests that the liver may be an important site of SLI metabolism.
We have described (13) an in vivo dog model for the estimation of peptide hormone metabolism. The present experiments were designed to study the in vivo metabolism of SLI and to assess the relative contribution of the liver and kidney to its metabolic clearance. The results indicate that both the liver and kidney are major sites of SLI degradation, together accounting for 70% of its overall metabolic clearance.
METHODS
18 mongrel dogs (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) kg) of both sexes were studied. Animals were observed for 1 wk before surgery to evaluate their general health status. After an overnight fast, anesthesia was induced with 30 mg/kg i.v. sodium pentobarbital (Diabutal, Diamond Laboratories Inc., Des Moines, Iowa) and maintained with boluses of 30-60 mg when necessary. The animals were intubated and artificially ventilated with a Bird pressure cycled ventilator with 40% oxygen supplementation.
Surgical procedures. The portal vein and hepatic artery were exposed, and electromagnetic flow probes (Gould Statham SP 2202) were placed around each vessel (Fig. 1) . The portal vein probe was placed 2 cm proximal to the bifurcation of this vessel into right and left portal trunks. The hepatic artery probe was positioned 2 cm distal to the origin of this vessel from the celiac trunk. Probes of appropriate size were chosen in each experiment to produce -30 and 15% constriction of the portal vein and hepatic artery, respectively, as recommended by Gordon et al. (14) . Before each experiment the flow probes were calibrated in saline and re- position of the checked after their placement to ensure that occlusion of the vessels recorded zero flows. The gastroduodenal branch of the hepatic artery was identified and ligated because this artery contributes to hepatic artery blood flow, while bypassing the liver. The gastroduodenal vein was also ligated as it entered the portal vein above the position where portal blood flow is measured. Bilateral ureteric catheters were inserted to ensure complete and accurate urine collection. End sampling catheters were placed in the portal vein, hepatic vein, left renal vein, and femoral artery in 10 animals ( Fig. 1) . In eight additional animals only portal and hepatic vein and femoral artery catheters were placed. The portal vein catheter was positioned so that its tip lay at the bifurcation of this vessel in the porta hepatis. The peripheral arterial catheter was inserted through a small branch of the left femoral artery into the common femoral artery. The hepatic vein catheter was passed through the right jugular vein into the left common hepatic vein 1-2 cm from the wedged position. The renal vein catheter was advanced through the left femoral vein into the left renal vein so that its tip lay as close to the renal hilum as possible. (17) . Under the assay conditions described there was no evidence of tracer degradation in plasma in excess of that seen in the presence of buffer alone, which was negligible. Recovery of cyclic somatostatin added to dog plasma and incubated at 4°C overnight was >85%.
The glucagon radioimmunoassay was performed with 30K antiserum (obtained from Dr. Unger, University of Texas, Southwestern Medical School, Dallas, Tex.) as described (19) using charcoal for separation of bound and free hormone. Insulin radioimmunoassay was performed as described (20 Renal metabolism of SLI. The renal extraction of exogenously infused SLI was 62.3±5% (n = 10) and remained stable over a wide range of circulating levels of the peptide. The amount of SLI extracted by the kidney also increased in a linear fashion as the amount delivered to the kidney increased (Fig. 4) . Renal extraction of SLI is therefore also nonsaturable over a wide range of arterial SLI levels.
The renal plasma flow was 240±21 ml/min. The clearance of inulin was 3.0±0.5 ml/kg per min, and its renal extraction was 26.7±3.6% (n = 10). The renal organ clearance of SLI was 7.0±1.1 ml/kg per min (n = 10). This was significantly greater than inulin clearance (P < 0.002). The urinary clearance of SLI was assessed in six experimental periods in three dogs. The levels were 26+7 pg/ml, which are negligible, representing <1% of the renal organ clearance of the peptide. These data suggest that renal extraction of SLI involves, in addition to filtration, uptake of the peptide from postglomerular peritubular blood. Furthermore, the negligible urinary excretion of intact SLI indicates that hormone removed from the renal circulation is degraded by the kidney.
MCR of SLI. The MCR, 19 .7±1.6 ml/kg per min (n = 17), was unchanged over the above range in arterial concentrations. In 10 animals in which metabolic, hepatic, and renal clearance rates were simultaneously measured, the contributions ofthe liver and the kidney to the overall metabolic clearance of SLI were calculated. In these animals, MCR ii 13 14 1.
in close agreement with results obtained by other workers (22) (23) (24) (25) , confirming the validity of our experimental model. All hormonal measurements were made, under steady-state conditions, eliminating the variability inherent in an experimental design in which hormonal levels are changing rapidly. Furthermore, the peripheral infusion of exogenous somatostatin ensured complete mixing of the peptide in the portal vein, thus eliminating the possibility that portal streaming of newly secreted endogenous SLI may result in nonrepresentative portal concentrations. In the accurate assessment of SLI metabolism two particular considerations require attention, namely validity of the radioimmunoassay of plasma SLI and the possible influence of the heterogeneity of plasma SLI on measured organ extraction.
One of the major problems encountered in the radioimmunoassay of plasma SLI is degradation of [125I-Tyrl]-somatostatin (10) . There is a marked species difference in this regard: human, rat, and baboon plasma show a much greater propensity for degradation of [125I-Tyr']-somatostatin than dog plasma (26) . In fact under the acid conditions of our assay and in the presence of Trasylol there is no evidence of tracer degradation after incubation with dog plasma for 24 h as judged by both immunoprecipitation and paper chromatoelectrophoresis. These findings are similar to those of Boldt et al. (26) . We have therefore found it unnecessary to use extraction techniques as described by others to overcome degradation of [1251-Tyrlisomatostatin (10, 27) .
There is much controversy surrounding the molecular forms of circulating SLI. Conlon et al. (28) found that at pH 8.8, endogenous as well as synthetic somatostatin added to dog plasma in small amounts eluted in the void volume of a Sephadex G-25 column. If synthetic somatostatin was added in conccntrations >5 ng/ml, a proportion coeluted with synthetic somatostatin. Under acid conditions SLI eluted with synthetic somatostatin, suggesting that somatostatin had been dissociated from a plasma binder. Patel et al. (10) found that rat portal plasma SLI contained equal amounts of immunoreactivity corresponding to the tetradecapeptide as well as material of molecular weight >5,000. The nature of this big SLI is unknown. Utsumi et al. (11) found that most SLI in rat plasma eluted with synthetic somatostatin, although a small amount was present in the void volume. Insignificant levels of void volume SLI were found under both acid and neutral chromatographic conditions. This study was not designed to identify the predominant form of circulating SLI normally present. Because our antibody recognizes the central portion of the somatostatin molecule it cannot distinguish between the intact tetradecapeptide and somatostatin molecules that have undergone N-terminal modifications. Thus the radioimmunoassay measures plasma somatostatin-like immunoreactivity and not strictly plasma somatostatin. After infusion of 1,600-dalton exogenous somatostatin, virtually all the somatostatin immunoreactivity eluted from the columns in the same position as synthetic somatostatin. The data presented relates to the metabolism of this plasma fraction. Furthermore the hepatic handling of endogenous SLI was the same as that of the SLI present after infusion of exogenous somatostatin, irrespective of the plasma level to which it was infused. Thus, even if somatostatin infusion alters the relative proportions of plasma SLI fractions, this did not affect the hepatic handling of the peptide.
The reasons for the apparent difference between the chromatographic profiles of plasma SLI in this study and others is uncertain. It may be due to differences in species, assay conditions, pH of buffer used to elute SLI from the columns, or different antibody specificities. In this regard we have found that different glucagon antibodies that show equivalent immunoreactivity with 3,500-dalton glucagon, have very different specificities with respect to void volume glucagon immunoreactivity (29) . This is a possible explanation for the low levels of big SLI measured in our assay. The data presented therefore represent the metabolism of an -1,600-mol wt SLI fraction only.
These studies indicate that in the dog, the liver and kidney are major sites of SLI metabolism. The liver extracted 29.4 ±2.3% of the SLI delivered to it and hepatic SLI clearance was 5.2±0.5 ml/kg per min. Renal SLI extraction was 62.3+±5% and renal clearance was 7.0±1.1 ml/kg per min. The extraction process in both liver and kidney was shown to be linear over a wide concentration range from physiological (<200 pg/ml) to high pharmacological levels. Therefore both organs exhibit an extremely large capacity for SLI extraction. No difference in the hepatic handling of endogenous and exogenous SLI was shown. The MCR of infused SLI was 19.7±1.6 ml/kg per min. The hepatic contribution to overall MCR was 32.7±4.6%, and the simultaneously measured renal contribution was 37±4.9%.
The site of metabolism of the 30% of infused SLI not accounted for by hepatic and renal metabolism is unknown. Because somatostatin is secreted by the gastro-intestinal tract (30) There are a number of similarities between the in vivo handling of somatostatin, insulin, and glucagon. The major sites of metabolism of all three peptides are kidney and liver. The renal handling of all three peptides is characterized by high extraction ratios and negligible urinary excretion of the intact molecule, suggesting that hormone removed by the kidney is degraded by this organ. In addition renal disposal of all three peptides involves both glomerular filtration and uptake from peritubular blood (21, 32) . Lastly, the renal metabolism of all three peptides in nonsaturable at very high plasma levels. All three peptides have a rapid half life when injected intravenously, although the half life of somatostatin (1.9 min) is faster than that of either insulin (4.5 min) or glucagon (4.2 min) (13) .
There are, however, certain differences in the metabolism of these three peptides. Insulin is degraded in the liver after initially binding to cell surface receptors (33) . Hepatic insulin extraction is saturable at high delivery rates that accompany high serum insulin levels (34) . This may be due to saturation of hepatic binding sites for insulin which have been suggested to mediate the hepatic metabolism of this hormone (33). Sonksen et al. (35) showed that in man, increasing peripheral insulin from basal levels of 16-216, ,uU/ml by exogenous insulin infusion lead to a fall in the MCR of insulin from 34 to 11.4 ml/kg per min. These authors suggested that since the major site of insulin metabolism is the liver, progressive saturation of the degradative process was presumably occurring largely in the liver. This interpretation is consistent with the observations of numerous workers that in the kidney, the other major site of insulin metabolism, extraction is nonsaturable. Experiments performed on the dog have provided data that confirm the impression of saturability of hepatic insulin metabolism2. Hepatic glucagon extraction, on the other hand, is nonsaturable until high pharmacologic plasma glucagon levels have been reached, and the metabolic clearance rate for glucagon is nonsaturable at very high infusion rates ofexogenous hormone (13) . In these studies we were unable to show saturation of SLI removal by the liver despite extremely elevated arterial levels of the peptide. This is in agreement with the findings of Sacks et al. (36) in an isolated perfused rat liver system. Metabolic clearance rate for SLI was also nonsaturable at these extremely high infusion rates. These differences may have some relevance to the mechanisms for hepatic peptide hormone metabolism. Binding of hormones to receptors is recognized to be a saturable process and in this light, the differences between the saturability of hepatic insulin extraction and nonsaturability of hepatic glucagon extraction are noteworthy. These observations might therefore be taken to support the suggestion (33) A number of studies have suggested that the hepatic metabolism of peptide hormones may be related to their biological effects on that organ. Proinsulin, which has -5-10% of the intrinsic activity of insulin (34) is also extracted by the liver to a much lesser extent than insulin. Hruska et al. (37) have shown that intact parathyroid hormone increases hepatic glucose output and is avidly extracted by the liver. The amino terminal fragment of parathyroid hormone, however, has no effect on hepatic glucose output and is not extracted to any significant degree. We have shown that the metabolically active 3,500 mol wt plasma glucagon component is extracted by the liver, whereas other molecular species of immunoreactive glucagon that do not have known metabolic actions are not extracted by the liver (12, 38) . The question of whether somatostatin has a role in regulating hepatic function is controversial. Although some investigators have suggested somatostatin directly affects hepatic gluconeogenesis and glycogenolysis (39) , others have argued that its effect on the liver is purely secondary to the suppressive action on insulin and glucagon secretion (40) . The fact that somatostatin is extracted by the liver to such a significant extent raises the possibility that it may have a physiological action on the liver.
In addition to the theoretical issues raised by the in vivo metabolism of somatostatin a number of practical implications arise. Because the percentage of hepatic extraction of the peptide varies considerably from animal to animal, the magnitude of hepatic extraction will not be known in any given animal. As a result of this, portal somatostatin levels cannot be accurately predicted from peripheral levels. It is also possible that in any given animal hepatic extraction of somatostatin may vary under different physiological conditions. Furthermore as a result of significant hepatic extraction, changes in portal somatostatin levels may not be appreciated in the periphery. This must be taken into consideration in studies attempting to elucidate the physiological importance of the peptide.
It has been suggested that somatostatin may be important in the treatment of diabetes (41) , gastrointestinal hemorrhage (42) , and acute pancreatitis (43) . Any therapeutic potential that it may have in these conditions would be severely limited by its rapid metabolic disposal. It is possible, however, that analogues less avidly degraded at these sites, may demonstrate greater therapeutic benefit.
